Horizon Pharma Inc.


Brean Capital Provides Key Takeaways On Horizon Pharma Following Meeting With Management

In a research report released today, Brean Capital analyst Difei Yang reiterated a Buy rating on Horizon Pharma (NASDAQ:HZNP) with a price target …

Brean Capital Sees High Growth Potential For Horizon Pharma; Sets $18 Price Target

Brean Capital analyst Difei Yang initiated coverage on shares of Horizon Pharma (NASDAQ:HZNP) with a Buy rating and a price target of $18, which represents a …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts